Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neuroendocrine Tumors 6Carcinoid Tumor 5Neoplasms 4Carcinoma 3Vipoma 2Neoplasm Metastasis 2Intestinal Obstruction 2Carcinoma, Islet Cell 2Somatostatinoma 1Recurrence 1Prostatic Neoplasms 1Primary Inoperable Thymoma 1Pleural Effusion 1Peritoneal Neoplasms 1Malignant Carcinoid Syndrome 1Lymphangiomyoma 1Lymphangioleiomyomatosis 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Diarrhea 1Chylous Ascites 1Chylothorax 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Ascites 1Adenoma, Islet Cell 1

Interventions

Octreotide 2Rocuronium 1Metoclopramide 1Methylprednisolone 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Intestinal Obstruction × Octreotide × Clear all
NCT04027348 2022-11-29

Palliative Management of Inoperable Malignant Bowel Obstruction

Roswell Park Cancer Institute

Phase 2 Terminated
15 enrolled 10 charts

Intestinal Obstruction

NCT00332696 2011-09-23

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Novartis

Phase 2 Completed
64 enrolled 17 charts
Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡